WO2005044283A1 - アレルギー体質改善剤 - Google Patents
アレルギー体質改善剤 Download PDFInfo
- Publication number
- WO2005044283A1 WO2005044283A1 PCT/JP2004/016676 JP2004016676W WO2005044283A1 WO 2005044283 A1 WO2005044283 A1 WO 2005044283A1 JP 2004016676 W JP2004016676 W JP 2004016676W WO 2005044283 A1 WO2005044283 A1 WO 2005044283A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrolyzate
- water
- dietary fiber
- soluble dietary
- ige
- Prior art date
Links
- 230000000172 allergic effect Effects 0.000 title claims abstract description 28
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 28
- 230000016784 immunoglobulin production Effects 0.000 claims abstract description 22
- 239000003112 inhibitor Substances 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 235000013325 dietary fiber Nutrition 0.000 claims description 34
- 206010020751 Hypersensitivity Diseases 0.000 claims description 21
- 230000007815 allergy Effects 0.000 claims description 18
- 208000026935 allergic disease Diseases 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 230000007062 hydrolysis Effects 0.000 abstract description 9
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 9
- 239000000835 fiber Substances 0.000 abstract 1
- 235000013311 vegetables Nutrition 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- 229920002752 Konjac Polymers 0.000 description 26
- 235000010485 konjac Nutrition 0.000 description 26
- 238000004519 manufacturing process Methods 0.000 description 26
- 244000247812 Amorphophallus rivieri Species 0.000 description 24
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 24
- 239000000252 konjac Substances 0.000 description 24
- 230000002401 inhibitory effect Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 210000002510 keratinocyte Anatomy 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 210000004698 lymphocyte Anatomy 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004241 Th2 cell Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 102000034238 globular proteins Human genes 0.000 description 2
- 108091005896 globular proteins Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940028885 interleukin-4 Drugs 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 240000001851 Artemisia dracunculus Species 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229920000855 Fucoidan Polymers 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000219925 Oenothera Species 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 244000117054 Rungia klossii Species 0.000 description 1
- 235000002492 Rungia klossii Nutrition 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000001383 blood group incompatibility Diseases 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000005299 metal allergy Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- CTYRPMDGLDAWRQ-UHFFFAOYSA-N phenyl hydrogen sulfate Chemical compound OS(=O)(=O)OC1=CC=CC=C1 CTYRPMDGLDAWRQ-UHFFFAOYSA-N 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 206010040400 serum sickness Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/736—Glucomannans or galactomannans, e.g. locust bean gum, guar gum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an allergic constitution ameliorating agent that has an inhibitory effect on IgE antibody production and is effective for improving allergic constitution.
- Type I allergy is allergic reaction with antibodies.
- type I allergy shows symptoms 2-3 minutes after contact with the antigen, and reaches its maximum in more than 10 minutes.
- Type IV allergy is called delayed allergy because lymphocytes are involved and the symptoms slowly appear 24 to 48 hours after the antigens enter the body.
- Type I allergies include atopic dermatitis, acute juvenile measles, bronchial asthma, hay fever, rhinitis, gastrointestinal allergy, etc., and are the most frequent.
- Type II allergies include hemolytic anemia, decreased platelets, blood group incompatibility, drug allergies, etc.
- Type III allergies include serum sickness, filamentous nephritis, chronic pneumonitis, rheumatoid arthritis, viral hepatitis
- Type IV allergies include contact dermatitis, tuberculosis, organ transplant rejection, metal allergies, etc.
- the pathogenesis of type I allergy involving IgE antibodies is considered as follows.
- various foreign antigens such as food antigens such as eggs, milk, and soybeans and inhalation pits such as mites and pollen enter the body, are taken up by antigen presenting cells, and are released to CD4 + T (helper T) cells.
- helper T cells that recognized antigens presented by antigen presenting cells Interacts with B cells to differentiate and proliferate B cells into antibody-producing cells.
- the helper T cells are mainly classified into type I helper T cells (Thl cells) that induce cell-mediated immunity and type II helper T cells (Th2 cells) that induce humoral immunity, depending on the type of cytodynamic force they produce ) (See, for example, Non-Patent Document 1).
- Thl cells produce interleukin 2 (IL-2), interferon gamma (IFN-y), TGF-j8, etc.
- Th2 cells have IL4, IL5, IL6, IL10 , IL-13 and the like. It is known that naive T cells that have not been sensitized to antigens are divided into Th1 cells when the antigen-presenting cell IL12 is acted on, and Th2 cells when the antigen-presenting cell and IL4 are acted on.
- B cells that have undergone the interaction of Th2 cells involved in the allergic reaction mature and grow into antibody-producing cells, produce IgM antibodies, and then IgGl antibodies, and finally produce IgE antibodies.
- B cells that have interacted with Thl cells mature and proliferate into antibody-producing cells that produce IgM, IgG2a, IgG2b, and IgG3 antibodies, but the most important function of Thl cells is that It is to activate macrophages by the action of the produced IFN- ⁇ to induce cell-mediated immunity.
- the produced IgE antibody binds to the surface of mast cells, and when a specific antigen binds to the IgE antibody, the mast cells are activated and inflammatory substances such as histamine are released, and allergic conditions are induced. I do. Mast cell force The released chemotactic factor induces eosinophils having an inflammatory effect and amplifies inflammation. Similarly, mast cells produce interleukin-4 (IL-4) and IL13. Further promote IgE antibody production by B cells.
- IL-4 interleukin-4
- Thl cells and Th2 cells have an aspect of mutually inhibiting the function of each other. For example, it is known that IFN- ⁇ produced by Thl cells suppresses the production of IgE antibodies. In a healthy state, the balance of ThlZTh2 cells is maintained, and IgE antibodies are not produced against invading antigens.However, in patients with allergies, the balance of ThlZTh2 cells is disturbed, and the invading antigens are more affected than Thl cells. It is thought that Th2 cells are in a predominantly responsive state, and that allergies involving IgE antibodies are likely to be induced.
- Patent Literature 1 Japanese Patent Publication No. 2003-513893
- Patent Document 2 Japanese Patent Application Laid-Open No. 2003-55233
- Non-Patent Document l Mosmann, T.R. et al .: J. Immunol., 136, 2348-2357, 1986
- Non-Patent Document 2 Standard Immunology Edit: Rokatani Tani, Masayuki Takasaka Medical Shoin 2001
- An object of the present invention is to provide an allergic constitution improving agent that is effective for improving allergic constitution, safe and easy to take.
- the present inventors have focused on the antiallergic effect of dietary fiber, and as a result of diligent studies, found that a polysaccharide obtained by hydrolyzing water-soluble dietary fiber has an excellent inhibitory effect on IgE antibody production.
- the present invention was also found to be useful as a medicine or food that exerts the effect of improving the allergic constitution immediately after inoculation, and completed the present invention.
- the present invention provides an allergic remedy containing a hydrolyzate of water-soluble dietary fiber as an active ingredient.
- the present invention also provides an IgE antibody production inhibitor containing a hydrolyzate of a water-soluble dietary fiber as an active ingredient.
- the present invention also provides an allergic constitution-improving food containing a hydrolyzate of a water-soluble dietary fiber.
- the present invention also provides use of a hydrolyzate of a water-soluble dietary fiber for producing an allergic constitution ameliorating agent.
- the present invention also provides use of a hydrolyzate of a water-soluble dietary fiber for producing an IgE antibody production inhibitor.
- the present invention also provides a method for improving an allergic constitution, which comprises administering a hydrolyzate of a water-soluble dietary fiber.
- the present invention also provides a method for suppressing IgE antibody production, which comprises administering a hydrolyzate of a water-soluble dietary fiber.
- the hydrolyzate of the water-soluble dietary fiber of the present invention has an inhibitory effect on IgE antibody production, and is therefore effective for improving the constitution of a person who is likely to develop type I allergy such as atopic dermatitis. is there.
- the hydrolyzate of the water-soluble dietary fiber of the present invention has a low molecular weight and is easily soluble, it can be used as a parenteral preparation such as an injection in addition to an oral preparation.
- the product of the present invention has no safety problems. It can be used as a safe and easily ingestible food from the elderly to infants.
- FIG. 1 is a graph showing the IgE production inhibitory effect of konjac dalcomannan hydrolyzate.
- FIG. 2 is a graph showing the IgE production inhibitory effect of a galatatomannan hydrolyzate.
- FIG. 3 is a gel filtration chromatograph of konjac dalcomannan hydrolyzed with different concentrations of hydrochloric acid.
- FIG. 4 is a graph showing the suppressive effect of konjac dalcomannan on IgE production hydrolyzed with different concentrations of hydrochloric acid.
- the hydrolyzate of the water-soluble dietary fiber As the hydrolyzate of the water-soluble dietary fiber, the above-mentioned water-soluble dietary fiber or a raw material containing the same, for example, konjac or pectin is hydrolyzed with an enzyme such as mannanase or pectinase, an acid, an alkali, or the like.
- an enzyme such as mannanase or pectinase, an acid, an alkali, or the like.
- the resulting decomposed product may be mentioned, but from the viewpoints of operability, reproducibility, economy and the like, those hydrolyzed with mineral acids, especially hydrochloric acid, are preferred.
- Conditions for the hydrolysis are not particularly limited, and may be appropriately selected according to the raw materials used.
- a water-soluble dietary fiber or a raw material containing the same is made into a solution of 0.1 to 5% by weight, and is usually used in an action pH range and an action temperature range of an enzyme to be used.
- the enzyme may be allowed to act for about 30 minutes to 20 hours.
- the hydrolysis using an acid-alkali may be carried out by making a water-soluble dietary fiber or a raw material containing the same into a 0.1 to 5% by weight solution, and allowing the acid-alkali to act.
- the concentration of hydrochloric acid is 0.05N-1.5N, preferably 0.125N-1N, and the hydrolysis temperature is 35N.
- the hydrolysis should be carried out within a range of 30 ° C. to 90 ° C., preferably 45 ° C. to 80 ° C., and a hydrolysis time of 30 minutes to 13 hours, preferably 1 hour to 12 hours.
- the obtained hydrolyzate can be separated and purified by a known method such as a centrifugation method, a column method, an ultrafiltration method, and the like, and then dried and used, if necessary.
- the hydrolyzate obtained by the above hydrolysis has a molecular weight of several hundred daltons (D
- KD kilodaltons
- the hydrolyzate of the water-soluble dietary fiber thus obtained has an inhibitory effect on IgE antibody production as shown in Examples described later. It can be used in the form of pharmaceuticals, foods, etc. as an allergic constitution ameliorating agent for improving the allergic constitution of persons who are likely to develop type I allergy such as dermatitis, bronchial asthma, allergic rhinitis and the like.
- the allergic constitution ameliorating agent and the IgE antibody production inhibitor of the present invention are used as pharmaceuticals, they can be formulated into any of oral preparations and parenteral preparations, for example, tablets, granules, capsules In addition to solid preparations such as powders, liquid preparations such as syrups and elixirs, injections, suppositories, inhalants (sprays), eye drops, and external preparations can be used.
- Such a preparation may be prepared in various dosage forms using a hydrolyzate of a water-soluble dietary fiber together with a pharmaceutically acceptable carrier according to a conventional method.
- a hydrolyzate of a water-soluble dietary fiber together with a pharmaceutically acceptable carrier according to a conventional method.
- excipients and, if necessary, binders, disintegrants, lubricants, coloring agents, flavoring agents, flavoring agents, etc. are added to the hydrolyzate of water-soluble dietary fiber.
- tablets, coated tablets, granules, powders, capsules and the like can be produced by a conventional method.
- carriers include, for example, water, ethyl alcohol, macrogol, various diluents such as propylene glycol, pH adjusters and buffers, stabilizers, further solubilizers, soothing agents, topical An anesthetic or the like may be appropriately added to prepare a subcutaneous, intramuscular, or intravenous injection according to a conventional method.
- the allergic constitution improving agent and the IgE antibody production inhibitor of the present invention are used as foods such as health foods and functional health foods, biscuits, chocolates, candy, chewing gums, snacks, oils Confectionery, ice cream, jelly confectionery, baked goods, noodles, soy products such as tofu, yogurt, butter, etc. It can be in the form of beverages such as sports drinks and soups.
- Such foods may be further blended with tea, shiso, tea, evening primrose, dandelion, persimmon leaves, wormwood, citrus, and the like, which are generally considered to be effective for allergies.
- the daily dose of the above allergic constitution ameliorating agent or IgE antibody production inhibitor depends on the patient's symptoms, weight, age, gender, etc., and cannot be determined unconditionally.
- hydrolysis of water-soluble dietary fiber It is usually sufficient to use about 30mg-30g, preferably about 100mg-3g per day for adults, and it is preferable to administer it once or twice or four times a day.
- the present invention will be described in more detail and specifically with reference to examples.
- Konjac darcomannan (Wako Pure Chemical Industries) was suspended in 2.4 mL of distilled water, and shaken in a 50 ° C water bath for 2 hours to prepare konjac gel. Hydrochloric acid was added thereto to a final concentration of 0.2N, and the mixture was shaken for 2 hours. After returning to room temperature, sodium hydroxide was added to neutralize the hydrochloric acid, and 0.5 mL of a 0.5 M phosphate buffer ((pH 6.5)) was added to the mixture to adjust the pH of the solution to 6.5.
- a 0.5 M phosphate buffer ((pH 6.5)
- the obtained hydrolyzate was centrifuged (10,000 rpm, 10 min) to remove insolubles, and the mixture was suspended on a Sepha cryl S-200 (IX 45 cm) (Amersham Bioscience) column and lOmM phosphate buffer (pH 6.
- the hydrolyzate of konjac dalcomannan was eluted at the eluate volume of 18-22.5 mL.
- the fractions were collected, dialyzed against a phosphate buffer, concentrated by an ultraconcentrator, and the concentration of the hydrolyzate as a sugar was measured by the phenol sulfate method.
- lymphocyte fraction is collected by specific gravity centrifugation using Lympholite-M (CedarLane Laboratories) did.
- the prepared lymphocytes contain IL 4 (R & D, final concentration 100 ng / mL), anti-zero 0-40 antibody (361: 06, final concentration 200 ng ZmL), and 2-mercap toethanol (final concentration 50 nM) It was adjusted to a concentration of 2 ⁇ 10 6 ZmL with ISCOV medium, and was dispensed at 180 / z LZWell into each well of a 96-well microplate.
- the obtained hydrolyzate was centrifuged (10000 rpm, 10 min) to remove insolubles, and the fraction was eluted with a 10 mM phosphate buffer (pH 6.5) by hanging on a SephacrylS-200 (1 X 45 cm) column.
- the hydrolyzate of galatatomannan was recovered at the elution position of 18-22.5 mL, dialyzed against phosphate buffer, and concentrated by an ultra-concentrator. The concentration was measured by the phenolic sulfuric acid method
- BalbZc mice (8 weeks old, o 71) spleens were Cell suspensions were prepared loosened in ISCOV medium was recovered lymphocyte fraction by further Lympholite- M density centrifugation method using (Cedarlane Laboratories Ltd.) .
- the obtained hydrolyzate was centrifuged (lOOOOrpm, lOmin) to remove insolubles, and then applied to a HiPrep 26/60 Sephacryl S-300HR (2.6 X 60cm) (Amersham Bioscience) column to lOmM phosphate buffer. And eluted with fractions (pH 6.5).
- a HiPrep 26/60 Sephacryl S-300HR 2.6 X 60cm
- eluted with fractions pH 6.5.
- the molecular weight fraction range of this gel filtration column is 10 KD to 1500 KD when estimated as a globular protein, and 2 KD to 400 KD when estimated as a dextran (Amersham Bioscience). Characteristic power of hydrolyzed konjak darcomannan molecule It is thought that the behavior is similar to the fractionation range of dextran. Thus, it was prepared in a wide molecular weight distribution range up to about ( Figure 3). Fractions were collected around the peak of each total sugar, and a series of hydrolysates covering the molecular weight range of 1 KD to several 100 KD could be prepared. The collected fractions were dialyzed against a phosphate buffer and concentrated using an ultra-concentrator corresponding to the expected molecular weight. The concentration of these hydrolysates as sugar was measured by the phenol sulfuric acid method.
- Example 4 Effect of konjac dalcomannan hydrolyzate on IgE production system by keratinocyte extract
- Atopic dermatitis causes itching of the skin, and a worsening of the symptoms leads to a worsening of the symptoms and a vicious cycle of increased itching. From this phenomenon, it is considered that keratinocytes (keratinocytes) destroyed by exposing the skin are the cause of the symptoms. It has been shown that administration of an extract of keratinocytes (PAM-212 cells) to BalbZc mice stimulates blood IgE production. It has also been shown that the addition of PAM-212 cell extract to the in vitro IgE production system using spleen cells of BalbZc mice significantly enhances IgE production (Yamamoto T, Kanek.
- BalbZc mouse (8 weeks old, o 71 ) spleen is loosened in ISCOV medium to prepare cell suspension, and lymphocyte fraction is collected by specific gravity centrifugation using Lympholite-M (CedarLane Laboratories) did.
- Lympholite-M Lympholite-M
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/578,914 US20070148209A1 (en) | 2003-11-11 | 2004-11-10 | Allergic constitution ameliorator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-381557 | 2003-11-11 | ||
JP2003381557A JP4728572B2 (ja) | 2003-11-11 | 2003-11-11 | アレルギー体質改善剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005044283A1 true WO2005044283A1 (ja) | 2005-05-19 |
Family
ID=34567283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/016676 WO2005044283A1 (ja) | 2003-11-11 | 2004-11-10 | アレルギー体質改善剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20070148209A1 (ja) |
JP (1) | JP4728572B2 (ja) |
WO (1) | WO2005044283A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051146A1 (ja) * | 2011-10-07 | 2013-04-11 | 株式会社 荻野商店 | 低分子量化こんにゃくグルコマンナンの製造方法およびこの方法により得られる低分子量化こんにゃくグルコマンナン |
JPWO2013051146A1 (ja) * | 2011-10-07 | 2015-03-30 | 株式会社荻野商店 | 低分子量化こんにゃくグルコマンナンの製造方法およびこの方法により得られる低分子量化こんにゃくグルコマンナン |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102241788B (zh) * | 2010-05-10 | 2013-07-03 | 辽宁诺康医药有限公司 | 一种葡甘露聚糖酸水解产物的制备方法 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02222659A (ja) * | 1989-02-27 | 1990-09-05 | Morinaga Milk Ind Co Ltd | 水溶性食物繊維およびその製造法 |
JPH02312542A (ja) * | 1989-05-30 | 1990-12-27 | Kibun Kk | 新規飲料 |
JPH03285640A (ja) * | 1990-03-31 | 1991-12-16 | Snow Brand Milk Prod Co Ltd | ガラクトマンナン分解物を含有する液状発酵乳および乳酸菌飲料の製造法 |
JPH0576310A (ja) * | 1991-09-20 | 1993-03-30 | Taiyo Kagaku Co Ltd | 卵黄又は全卵を含有する粉末及びその製造方法 |
JPH05246860A (ja) * | 1992-02-20 | 1993-09-24 | Morinaga Milk Ind Co Ltd | 大腸ガン予防剤 |
JPH07330617A (ja) * | 1994-06-10 | 1995-12-19 | Meiji Milk Prod Co Ltd | アレルギー性疾患予防及び治療剤 |
JPH09208475A (ja) * | 1996-02-02 | 1997-08-12 | Kibun Food Chemifa Co Ltd | 抗アレルギー剤および抗炎症剤 |
WO2001013925A1 (fr) * | 1999-08-20 | 2001-03-01 | Takara Shuzo Co., Ltd. | Medicaments |
JP2001233777A (ja) * | 2000-02-25 | 2001-08-28 | Yakult Honsha Co Ltd | アレルギー性疾患予防・治療剤 |
WO2002042484A2 (de) * | 2000-11-22 | 2002-05-30 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Verfahren zur herstellung von pektinhydrolyseprodukten |
JP2002539809A (ja) * | 1999-03-26 | 2002-11-26 | エヌ・ヴイ・ヌートリシア | 若干負に帯電された不可消化性多糖類を含有する栄養調合物及び密着結合を通じての移動を低減するためのその使用 |
JP2003081841A (ja) * | 2001-06-26 | 2003-03-19 | Kikkoman Corp | 抗アレルギー体質強化剤 |
JP2003513893A (ja) * | 1999-09-29 | 2003-04-15 | エヌ・ヴイ・ヌートリシア | 非消化性多糖を含有する栄養性組成物および密接帯を介する輸送を減少するためのその使用 |
JP2004107295A (ja) * | 2002-09-20 | 2004-04-08 | National Agriculture & Bio-Oriented Research Organization | ヒスタミン遊離抑制剤 |
JP2004224772A (ja) * | 2003-01-27 | 2004-08-12 | Asahi Breweries Ltd | サッカロミセス酵母のマンナンを有効成分とするアレルギー体質改善剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06702B2 (ja) * | 1986-11-05 | 1994-01-05 | 花王株式会社 | 抗アレルギ−剤 |
JP4180258B2 (ja) * | 2001-08-06 | 2008-11-12 | 西川ゴム工業株式会社 | IgE抗体抑制剤および食品 |
-
2003
- 2003-11-11 JP JP2003381557A patent/JP4728572B2/ja not_active Expired - Fee Related
-
2004
- 2004-11-10 WO PCT/JP2004/016676 patent/WO2005044283A1/ja active Application Filing
- 2004-11-10 US US10/578,914 patent/US20070148209A1/en not_active Abandoned
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02222659A (ja) * | 1989-02-27 | 1990-09-05 | Morinaga Milk Ind Co Ltd | 水溶性食物繊維およびその製造法 |
JPH02312542A (ja) * | 1989-05-30 | 1990-12-27 | Kibun Kk | 新規飲料 |
JPH03285640A (ja) * | 1990-03-31 | 1991-12-16 | Snow Brand Milk Prod Co Ltd | ガラクトマンナン分解物を含有する液状発酵乳および乳酸菌飲料の製造法 |
JPH0576310A (ja) * | 1991-09-20 | 1993-03-30 | Taiyo Kagaku Co Ltd | 卵黄又は全卵を含有する粉末及びその製造方法 |
JPH05246860A (ja) * | 1992-02-20 | 1993-09-24 | Morinaga Milk Ind Co Ltd | 大腸ガン予防剤 |
JPH07330617A (ja) * | 1994-06-10 | 1995-12-19 | Meiji Milk Prod Co Ltd | アレルギー性疾患予防及び治療剤 |
JPH09208475A (ja) * | 1996-02-02 | 1997-08-12 | Kibun Food Chemifa Co Ltd | 抗アレルギー剤および抗炎症剤 |
JP2002539809A (ja) * | 1999-03-26 | 2002-11-26 | エヌ・ヴイ・ヌートリシア | 若干負に帯電された不可消化性多糖類を含有する栄養調合物及び密着結合を通じての移動を低減するためのその使用 |
WO2001013925A1 (fr) * | 1999-08-20 | 2001-03-01 | Takara Shuzo Co., Ltd. | Medicaments |
JP2003513893A (ja) * | 1999-09-29 | 2003-04-15 | エヌ・ヴイ・ヌートリシア | 非消化性多糖を含有する栄養性組成物および密接帯を介する輸送を減少するためのその使用 |
JP2001233777A (ja) * | 2000-02-25 | 2001-08-28 | Yakult Honsha Co Ltd | アレルギー性疾患予防・治療剤 |
WO2002042484A2 (de) * | 2000-11-22 | 2002-05-30 | Südzucker Aktiengesellschaft Mannheim/Ochsenfurt | Verfahren zur herstellung von pektinhydrolyseprodukten |
JP2003081841A (ja) * | 2001-06-26 | 2003-03-19 | Kikkoman Corp | 抗アレルギー体質強化剤 |
JP2004107295A (ja) * | 2002-09-20 | 2004-04-08 | National Agriculture & Bio-Oriented Research Organization | ヒスタミン遊離抑制剤 |
JP2004224772A (ja) * | 2003-01-27 | 2004-08-12 | Asahi Breweries Ltd | サッカロミセス酵母のマンナンを有効成分とするアレルギー体質改善剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013051146A1 (ja) * | 2011-10-07 | 2013-04-11 | 株式会社 荻野商店 | 低分子量化こんにゃくグルコマンナンの製造方法およびこの方法により得られる低分子量化こんにゃくグルコマンナン |
JPWO2013051146A1 (ja) * | 2011-10-07 | 2015-03-30 | 株式会社荻野商店 | 低分子量化こんにゃくグルコマンナンの製造方法およびこの方法により得られる低分子量化こんにゃくグルコマンナン |
Also Published As
Publication number | Publication date |
---|---|
JP2005145831A (ja) | 2005-06-09 |
US20070148209A1 (en) | 2007-06-28 |
JP4728572B2 (ja) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5031249B2 (ja) | 炎症抑制作用のある菌体含有組成物 | |
US9737575B2 (en) | Use of lactic acid bacteria to treat or prevent eczema | |
TW201709917A (zh) | 包含細菌菌株之組合物 | |
KR20080091743A (ko) | 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물 | |
TW200829175A (en) | Anti-allergy lactic acid bacteria | |
RU2671209C2 (ru) | Lactobacillus rhamnosus rht-3201, конъюгированные с полисахаридным полимерным связующим и их применение для профилактики или лечения атопических заболеваний | |
JP2004521919A (ja) | 抗ストレス機能、抗疲労機能、月経前期症候群及び月経痛緩和機能及び脳神経栄養因子としての機能を有する酵母由来機能性ペプチド及びその製造方法 | |
MX2012009945A (es) | Preparacion que contiene bacteria de acido lactico. | |
AU2008241977A1 (en) | Composition comprising lactic acid bacterium having high anti-allergic activity, and method for production of the lactic acid bacterium | |
JP2019201590A (ja) | 免疫賦活用組成物及びサイトカイン産生促進用組成物 | |
US20230136694A1 (en) | Pharmaceutical composition for preventing or treating atopic disease containing akkermansia muciniphila strain | |
KR102186420B1 (ko) | 스타필로코커스 석시너스 14bme20 균주를 유효성분으로 포함하는 알레르기 질환의 예방, 개선 또는 치료용 조성물 | |
JP5550802B2 (ja) | 免疫調整作用のあるメロン抽出物含有組成物 | |
JP4728572B2 (ja) | アレルギー体質改善剤 | |
WO2011099875A1 (en) | Use of lactic acid bacteria to treat or prevent rhinitis | |
AU782539B2 (en) | Antigen-specific IgE antibody production inhibitors | |
JP2007054081A (ja) | ハスの破砕物および/または抽出物と、乳酸菌とを含む抗アレルギー用食品 | |
KR100866911B1 (ko) | 유산균 및 콜라겐을 유효성분으로 포함하는 관절염 예방 및치료용 조성물 | |
JP3947778B2 (ja) | ハスの破砕物および/または抽出物と、乳酸菌とを含む抗アレルギー剤 | |
US20170224746A1 (en) | Nutritional Support Method For Health Issues | |
JP7539230B2 (ja) | 免疫バランスの調節のための組成物 | |
TW201210509A (en) | Anti-allergy lactic acid bacteria | |
JP7015674B2 (ja) | 制御性t細胞の分化誘導剤及び分化誘導方法 | |
TWI281859B (en) | Medical composition for treating respiratory allergic disease | |
JP2006257040A (ja) | アレルゲン特異的IgE抗体産生抑制剤、及びアレルゲン特異的IgE抗体産生抑制のために用いられる飲食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007148209 Country of ref document: US Ref document number: 10578914 Country of ref document: US |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTIFICATION OF LOSS OF RIGHTS PURSUANT TO RULE 69(1) EPC (FORM 1205A SENT ON 17.08.06). |
|
WWP | Wipo information: published in national office |
Ref document number: 10578914 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |